Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sancai Fengsui Decoction is a Traditional Chinese Medicine (TCM) herbal compound currently in Phase 2 clinical development for the treatment and rehabilitation of radiation-induced oral mucositis (RTOM) in patients with head and neck cancer. Developed by Nanfang Hospital of Southern Medical University, the formula is a combination of two classic TCM prescriptions: Sancai Dan (comprising *Panax ginseng*, *Asparagus cochinchinensis*, and *Rehmannia glutinosa*) and Fengsui Dan (comprising *Phellodendron chinense*, *Amomum villosum*, and *Glycyrrhiza uralensis*). The decoction is hypothesized to alleviate the "yin deficiency and fire flourishing" state often associated with radiotherapy-induced tissue damage. Mechanistically, it is thought to exert anti-inflammatory and antioxidant effects, reducing oral pain and promoting the healing of the oral mucosa while improving symptoms of xerostomia.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Sancai Fengsui Decoction.